Cyclo Therapeutics, Inc. CYTH
Set alert
0.72 0.00 0.00%
At close · Mar 26
0.7206 Day range 0.7206
52-week range unavailable
- YTD
- +22.14%
- 1 year
- -49.61%
- Open
- 0.7206
- Prev close
- 0.7206
- Mkt cap
- 17.32M
- Vol
- 186.81K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7206
- High
- 0.7206
- Forward P/E
- -0.91
- Beta
- -0.38
- Short ratio
- 3.82
- Inst. own
- 13.17%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6972
- 200-d avg
- 1.06
- 1y target
- 0.95
Key statistics
- Market cap
- 17.32M
- Enterprise value
- 19.51M
- Trailing P/E
- 0.00
- Forward P/E
- -0.91
- PEG ratio
- 0.00
- Price / sales
- 15.29
- Price / book
- 3.60
- EPS (TTM)
- -0.90
- Beta
- -0.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.13M
- Revenue growth
- 5.10%
- Free cash flow
- -10.79M
- Total cash
- 1.12M
- Total debt
- 3.00M
- Return on equity
- 0.00%
- Shares outstanding
- 28.61M
- Short % of float
- 0.46%
- 50-day average
- 0.6972
- 200-day average
- 1.06
Analyst view
Consensus: none
Price target (mean) 0.95
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
CYTH Revenue — quarterly 233.77K
CYTH Net income — quarterly -8.83M
CYTH EPS — quarterly -0.31
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.17 | -0.26 | -0.09 | -52.94% |
| Aug 14, 2024 | Jun 1, 2024 | -0.14 | -0.21 | -0.07 | -50.00% |
| May 15, 2024 | Mar 1, 2024 | -0.20 | -0.15 | +0.05 | +25.00% |
| Mar 18, 2024 | Dec 1, 2023 | 0.00 | -0.23 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.29 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -0.33 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Maxim Group | down | Buy | Hold |
| Aug 26, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 23, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 1, 2024 | HC Wainwright & Co. | init | — | Buy |
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- cyclotherapeutics.com
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
- Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
- Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
Your note
Sign in to keep a note on CYTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CONKLING WILLIAM | Director | Stock Award(Grant) | Nov 14, 2024 | 50,230 |
| CROSS SHAWN M. | Director | Stock Award(Grant) | Nov 14, 2024 | 107,749 |
| FINE N SCOTT | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 19, 2023 | 743,804 |
| OSTRONIC FRANCIS PATRICK | Director | Stock Award(Grant) | Jun 2, 2024 | 348,771 |
| SHANAHAN WILLIAM S | Director | Stock Award(Grant) | Nov 14, 2024 | 148,826 |
| SIEGER MARKUS | Director | Stock Award(Grant) | Nov 14, 2024 | 382,122 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EPIQ Capital Group, LLC | 2.57% | 739,426 | 445.13K | Sep 29, 2024 |
| Vanguard Group Inc | 2.08% | 598,694 | 360.41K | Sep 29, 2024 |
| Founders Fund V Management, LLC | 1.67% | 480,708 | 289.39K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.53% | 152,332 | 91.70K | Sep 29, 2024 |
| Founders Fund VI Management, LLC | 0.38% | 110,023 | 66.23K | Sep 29, 2024 |
| Blackrock Inc. | 0.29% | 83,521 | 50.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.52% | 437,611 | 263.44K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 161,083 | 96.97K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 96,073 | 57.84K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 43,615 | 26.26K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 17,413 | 10.48K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 13,730 | 8.27K | Oct 30, 2024 |